Skip to main content
OpenTrials
Completed

NCT Number: NCT00732823

Compression Device Safety Study

To evaluate the safety of the Compression Device to subjects with venous insufficiency and oedema.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Hautarzt Phlebologe Allergologe

Freiburg im Breisgau, Germany

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects over 18 years, willing and able to provide written informed consent.
  • Subjects able to wear the Amadeus device and follow the requirements of the clinical investigation plan
  • Subjects who have an ankle to brachial pressure index (ABPI) of ABPI >0.8
  • Subjects with chronic lower limb oedema (i.e. CEAP classification of C3, C4 or C5 1.)
  • Subjects who have Chronic Venous Insufficiency (CVI), which has been present for 6 weeks or longer and who have refluxes >0.5 sec in one or more major venous segments, superficial or deep or both (CEAP classification: C3-C5 1.; Ep,s; As,d; Pr).

Exclusion criteria

  • Subjects with a history of skin sensitivity to any of the components of the study product.
  • Subjects who have previously been entered into the study before
  • Subjects who have a history of Deep Vein Thrombosis (DVT) within the last 6 months
  • Subjects who have an active leg ulcer (i.e. CEAP classification of C6 1).
  • Subjects with active cardiac disease or significant history of cardiac disease (including history of myocardial infarction, heart failure, valvular disease, arrhythmia and those with a pacemaker or have previously had a pacemaker).
  • Subjects who have initiated treatment or changed the dose within the past month of pharmaceutical agents that reduce clotting e.g. aspirin (except low-dose aspirin), anti-platelets, anti-coagulants and coumarin.
  • Subjects who are currently taking pharmaceutical agents that can modify the amount of leg oedema (e.g., diuretics, dihydropyridine calcium channel blockers, phlebotonic drugs, or fluctuating doses of systemic steroids) or have taken these agents within the last 10 days.
  • Subjects who are pregnant
  • Subjects who have worn compression therapy in the last 48 hours
  • Subjects who have leg sizes outside the following range:
  • Ankle 17cm - 32cm
  • Calf 27cm - 47cm
  • Below Knee 29cm - 51cm

Treatment and study plan

Placebo - No device worn

Device

Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs

Device

Primary outcomes

  1. The nature and frequency of adverse events

  2. Distal arterial flow

Secondary outcomes

  1. Volume reduction will be measured by recording limb volume at the start and end of each profile for both legs. The test leg will be compared to baseline and the contralateral leg. Comfort during wear will be recorded on completion of each profile

Sponsors and collaborators

Lead sponsor

ConvaTec Inc.

Industry

Collaborators

  • Bristol-Myers Squibb

Registry information

Official study title

A Phase II Randomized Study to Evaluate the Safety of the Compression Test Device Using Intermittent Pneumatic Compression Mode in Subjects With Venous Insufficiency and Oedema

Important dates

Study start
2005
Primary completion
2005
Study completion
2005
First posted
Aug 12, 2008
Registry last updated
Oct 31, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.